INS and type 1 diabetes mellitus: A follow-up study by the same group [77] extended the supplementation to 12 months and observed further reductions in fasting plasma glucose (from 115.6 ± 14.5 to 100.2 ± 17.4 mg/dL) and insulin requirement (from 30.4 ± 11.97 to 19.12 ± 13.39 units/day), supporting the potential of CM to improve metabolic regulation in T1DM.